Vaccinogen develops OncoVAX, a patented patient-specific vaccine that uses a patient’s own live tumor cells to elicit an immune response intended to prevent recurrence of colon cancer. Five clinical studies have been completed, and a prior Phase III showed recurrence reduced from roughly one in three to one in ten Stage 2 colon cancer patients. The company is preparing to start ACTIVE, a confirmatory Phase IIIb pivotal study under an FDA Special Protocol Assessment and expects to begin within 60 days of obtaining adequate funding. Vaccinogen operates a Dutch cGMP manufacturing facility and is building clinical and technical teams to support late‑stage development. Recent financing and board/management changes are intended to support progression through the final stages of OncoVAX development. The company announced management changes including Andrew L. Tussing named CEO and Benjamin S. Carson, Sr., MD appointed Chairman of the Board. Vaccinogen is a biotech company based in Frederick, Md., that develops OncoVAX, an immunotherapy for State II colon cancer. The article reports the company raised $6.6 million in equity, according to SEC filings. No investors or use-of-proceeds details were disclosed in the report. The piece did not provide operating metrics, prior financings, or a development timeline. All information is drawn from Technical.ly's Startup Roundup citing SEC filings.

Total raised

$17M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2014